Interim Report for the period January – March 2022
Decision on marketing approval for lecanemab is approaching Events during the first quarter 2022 · Eisai commenced submission of lecanemab data in Japan for a prior assessment consultation, with the objective of obtaining faster regulatory marketing approval. Events after the first quarter · AbbVie took a strategic business decision to end its collaboration with BioArctic regarding its alpha-synuclein portfolio, including ABBV-0805. BioArctic will now, in accordance with the license agreement, take back the project and evaluate the best way forward. · A recently